Import Doa Rapid Test — Buy in Bulk from Supplier in China

The DOA rapid test from World Of Health Biotech Co., Ltd. is a lateral flow immunoassay designed to detect Follicle Stimulating Hormone (FSH) in urine samples. Each test strip measures 5 mm in width and 80 mm in length, with a nitrocellulose membrane substrate and gold nanoparticle conjugates. The test is calibrated to detect FSH concentrations between 5 IU/L and 100 IU/L, a range relevant for fertility assessment and menopausal monitoring.

The test uses a sandwich immunoassay format with two monoclonal antibodies: one for capture and one for detection. The sample pad is treated with surfactants to reduce viscosity interference, and the conjugate pad contains stabilised gold-antibody complexes. These are standard components for FSH tests, but the supplier does not disclose the antibody clone sources or conjugation chemistry. The shelf life is 24 months when stored at 2°C to 30°C.

This product is purchased by fertility clinics, reproductive health labs, and private diagnostic distributors who require point-of-care hormone testing. Buyers typically order in batches of 10,000 to 50,000 units for distribution. Packaging is in individual foil pouches with desiccant, and the supplier offers FOB Shanghai and CIF port options. Lead time for standard orders is 15 to 25 days after payment.

World Of Health Biotech Co., Ltd. is a supplier based in Beijing, China, with a registered business address and classification as an imported supplier. The listing provides no details on manufacturing capacity, workforce, or internal quality systems. The supplier is listed under the 'harbor' trust tier, indicating basic verification only. There is no public information on certifications, clinical validation studies, or export history.

The supplier has no recorded response rate or average response time, suggesting limited communication capacity. The source description mentions ISO and CE certifications, but these are not verified in the data provided. No laboratory, production facility, or quality control documentation is disclosed. Buyers must treat this as a trading entity unless independent evidence of production capability is obtained.